Abemaciclib (LY2835219) in Men With Heavily Treated Metastatic Castration-Resistant Prostate Cancer
Completed · Phase 2 · NCT04408924
Conditions: Metastatic Castration-Resistant Prostate Cancer
At a glance
- Research payments reported, 2025
- $5,366
- U.S. investigators named
- 1
- Sites paid
- 1
- Planned or actual enrollment
- 44
About the trial
- Sponsor
- Eli Lilly and Company
- Tested
- Abemaciclib (drug)
- Dates
- Started 2021-01-20; completion 2023-06-02
- Results posted
- Yes
The study will evaluate how safe and effective abemaciclib is when given to participants whose metastatic prostate cancer progresses after they had received several previous treatments.
From ClinicalTrials.gov, last updated 2024-06-25. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Eli Lilly and Company reported $5,366 in research payments for this study in 2025 (1 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.